|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||HG9 cell line (small cell lung carcinoma)|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:10-1:200|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This product requires protein digestion pre-treatment of paraffin sections using trypsin or pronase. A suggested positive control for immunohistochemical applications is large bowel. For FACS analysis, use 10ul of the suggested working dilution to label 1x10^6 cells in 100ul.
This product is a low-endotoxin, preservative-free formulation.
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008]
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.
MA5-16973 was used in immunocytochemistry to review the current state-of-the-art in circulating tumor cell profiling
|Becker TM,Caixeiro NJ,Lim SH,Tognela A,Kienzle N,Scott KF,Spring KJ,de Souza P||International journal of cancer (134:2523)||2014|
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker.
MA5-16973 was used in immunocytochemistry and immunohistochemistry - paraffin section to investigate epithelial to mesenchymal transition during metastasis of pancreatic cancer
|Khoja L,Backen A,Sloane R,Menasce L,Ryder D,Krebs M,Board R,Clack G,Hughes A,Blackhall F,Valle JW,Dive C||British journal of cancer (106:508)||2012|
Neuropilin-2 Is upregulated in lung cancer cells during TGF-ß1-induced epithelial-mesenchymal transition.
MA5-16973 was used in western blot to study TGF-beta1-driven lung cancer cell epithelial-to-mesenchymal transition and the role played by neuropilin-2
|Nasarre P,Gemmill RM,Potiron VA,Roche J,Lu X,Barón AE,Korch C,Garrett-Mayer E,Lagana A,Howe PH,Drabkin HA||Cancer research (73:7111)||2013|
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
MA5-16973 was used in western blot to study the role of ZEB1 in mediating the growth of malignant pleural mesothelioma cells
|Horio M,Sato M,Takeyama Y,Elshazley M,Yamashita R,Hase T,Yoshida K,Usami N,Yokoi K,Sekido Y,Kondo M,Toyokuni S,Gazdar AF,Minna JD,Hasegawa Y||Annals of surgical oncology (19 Suppl 3:S634)||2012|
Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
MA5-16973 was used in flow cytometry to study the different molecular phenotype and tumorigenicity of 5 breast cancer cell lines derived from a single patient
|Mosoyan G,Nagi C,Marukian S,Teixeira A,Simonian A,Resnick-Silverman L,DiFeo A,Johnston D,Reynolds SR,Roses DF,Mosoian A||PloS one (8:null)||2013|
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.
MA5-16973 was used in immunohistochemistry to identify genes differentially expressed in ovaraian serous adenocarcinoma as compared to healthy ovarian tissue
|Bauerschlag D,Bräutigam K,Moll R,Sehouli J,Mustea A,Salehin D,Krajewska M,Reed JC,Maass N,Hampton GM,Meinhold-Heerlein I||Journal of cancer research and clinical oncology (139:347)||2013|